NDAINTRAVENOUSPOWDER
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
LOCAMETZ (kit for the preparation of gallium ga 68 gozetotide) by Novartis is 68 gozetotide binds to psma. First approved in 2022.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOCAMETZ is a gallium-68 labeled radiopharmaceutical kit for preparing gozetotide, a PSMA-targeting PET imaging agent used in prostate cancer diagnosis and staging. Gozetotide binds to prostate-specific membrane antigen (PSMA) expressed on malignant prostate cancer cells, enabling positron emission tomography detection via gallium-68's β+ emissions. This diagnostic agent facilitates precise localization and assessment of PSMA-positive disease.
Peak9.5 years to LOE
Recently approved product in peak growth phase with no direct competitors, suggesting expanding commercial teams and market development opportunities.
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows PET.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOCAMETZ offers careers in a high-growth, differentiated diagnostic space within oncology with minimal direct competition and strong clinical value proposition. The product's peak-stage status and 9+ years of patent protection create stability for mid-to-senior pharma professionals in commercial, medical, and strategic roles.
Brand Manager
Worked on LOCAMETZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.